As more drugs go subcutaneous, Phillips Medisize's director of Front-End Innovation, Tony Bedford, believes that high-dose biologics will become a prevalent choice for drugmakers.

In a study published in the Journal of Extracellular Vesicles, scientists from the UF Health Cancer Institute have found a way to make treatment for a notoriously aggressive breast cancer more ...